Abstract
INTRODUCTION: and study aim: Individuals classified as high-risk at initial colonoscopy face an elevated risk of metachronous advanced colorectal neoplasms (meta-ACRN), but risk heterogeneity within this group remains unclear. We aimed to stratify meta-ACRN risk among high-risk individuals based on their synchronous neoplastic burden. METHODS: This prospective cohort study used data from a Taiwanese multicenter trial (NCT03373136). We included participants with conventional high-risk findings (3–10 low-risk adenomas [LRAs] or any high-risk adenoma [HRA]). The primary outcome was meta-ACRN incidence. Adjusted incidence rate ratios (aIRRs) were calculated using multivariable Poisson regression, stratifying patients by baseline synchronous burden, with the 3–4 LRAs group as reference. RESULTS: Among 730 participants undergoing surveillance (mean follow-up 2.4 years), 81 (11.1%) developed meta-ACRN. A single HRA did not significantly increase meta-ACRN risk compared with 3–4 LRAs (aIRR 2.02; 95% confidence interval (CI) 0.83–4.90). However, risk escalated significantly when the index HRA was accompanied by synchronous LRA(s) (aIRR 2.56; 95% CI 1.24–5.39) or synchronous HRA(s) (aIRR 3.93; 95% CI 1.77–8.73) ( P for trend = 0.001). Furthermore, applying a more severe modified advanced adenoma criteria, an identical dose-response pattern emerged, culminating in a >5-fold increased risk of severe metachronous outcomes (aIRR 5.23; 95% CI 1.50–18.22) when accompanied by synchronous HRA(s). DISCUSSION: Meta-ACRN risk within the conventional high-risk population is highly heterogeneous and driven primarily by baseline synchronous neoplastic burden. Surveillance intervals should be personalized, reserving shorter intervals for patients with advanced lesions accompanied by synchronous adenomas.
Funding Information
  • National Science and Technology Council (NSTC 113-2640-B-002-005)
  • E-Da Hospital (EDAHS114034)

This publication has 27 references indexed in Scilit: